Evaluation of CCL2 as a potential biomarker of pulmonary vascular disease in limited cutaneous systemic sclerosis
M. T. Carulli, CP Denton(The Royal Free Hospital), Gerry Coghlan(Papworth Hospital NHS Foundation Trust), Casilda G. Black, Dietmar Abraham(Medical University of Vienna)
UCL Discovery (University College London)
September 1, 2004
Cited by 1
Related Papers
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
|Nature Communications|2018|395
Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation
|Journal of Biological Chemistry|2000|219